New drug combo aims to boost Radiation's punch against tough GI cancers
NCT ID NCT02381561
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The drug is designed to make tumor cells more sensitive to radiation therapy. Researchers aim to find the safest dose and see how well the body processes the drug. About 19 participants with cancers of the esophagus, stomach, liver, pancreas, or bowel will take the drug before receiving palliative radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Conditions
Explore the condition pages connected to this study.